Actinium Pharmaceuticals, Inc. (ATNM) 10-Year Financial Performance & Capital Metrics

ATNM • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutActinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.Show more

Revenue $0 -100.0%
EBITDA -$41M +19.2%
Net Income -$38M +21.7%
EPS (Diluted) -1.27 +30.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -110.63% -16.5%
ROIC -
Debt/Equity 0.05 -17.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 13.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM11.11%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM15.44%

EPS CAGR

10Y-

5Y-

3Y-

TTM21.43%

ROCE

10Y Avg-131.46%

5Y Avg-51.93%

3Y Avg-52.26%

Latest-59.45%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	1.14M	1.03M	81K	0
Revenue Growth %	-	-	-	-	-	-	-	-0.1%	-0.92%	-1%
Cost of Goods Sold+	0	77.52K	55.94K	50.72K	420.09K	447K	524K	0	0	811K
COGS % of Revenue	-	-	-	-	-	-	0.46%	-	-	-
Gross Profit+	-53.47K	-77.52K	-55.94K	-50.72K	-420.09K	-447K	620K	1.03M	81K	-811K
Gross Margin %	-	-	-	-	-	-	0.54%	1%	1%	-
Gross Profit Growth %	-	-0.45%	0.28%	0.09%	-7.28%	-0.06%	2.39%	0.66%	-0.92%	-11.01%
Operating Expenses+	24.83M	26.85M	26.91M	23.83M	21.65M	21.95M	25.58M	35.13M	52M	41.31M
OpEx % of Revenue	-	-	-	-	-	-	22.36%	34.11%	641.99%	-
Selling, General & Admin	11.46M	9.27M	9.15M	6.73M	5.1M	6.31M	8.08M	12M	13.33M	12.08M
SG&A % of Revenue	-	-	-	-	-	-	7.06%	11.65%	164.58%	-
Research & Development	13.31M	17.5M	17.7M	17.09M	16.55M	16.09M	17.51M	23.14M	38.67M	30.05M
R&D % of Revenue	-	-	-	-	-	-	15.3%	22.46%	477.41%	-
Other Operating Expenses	53.47K	77.52K	55.94K	0	0	-447K	0	0	0	-811K
Operating Income+	-24.83M	-26.85M	-26.91M	-23.83M	-22.07M	-22.39M	-24.96M	-34.1M	-51.92M	-42.12M
Operating Margin %	-	-	-	-	-	-	-21.82%	-33.11%	-640.99%	-
Operating Income Growth %	-0.1%	-0.08%	-0%	0.11%	0.07%	-0.01%	-0.11%	-0.37%	-0.52%	0.19%
EBITDA+	-24.78M	-26.77M	-26.86M	-23.78M	-21.65M	-21.95M	-24.44M	-33.41M	-51.13M	-41.31M
EBITDA Margin %	-	-	-	-	-	-	-21.36%	-32.43%	-631.23%	-
EBITDA Growth %	-0.1%	-0.08%	-0%	0.11%	0.09%	-0.01%	-0.11%	-0.37%	-0.53%	0.19%
D&A (Non-Cash Add-back)	53.47K	77.52K	55.94K	50.72K	420.09K	447K	524K	699K	790K	811K
EBIT	-24.83M	-26.85M	-26.91M	-23.83M	-21.9M	-22.21M	-24.77M	-34.1M	-51.92M	-38.24M
Net Interest Income+	0	0	0	0	0	178K	190K	1.09M	3.1M	3.88M
Interest Income	0	0	5.43K	173.36K	172.39K	178K	190K	1.09M	3.1M	3.88M
Interest Expense	7.87K	5.01K	5.43K	173.36K	0	0	0	0	0	0
Other Income/Expense	3.8M	2.53M	309.55K	173.36K	172.39K	178K	190K	1.09M	3.1M	3.88M
Pretax Income+	-21.02M	-24.32M	-26.6M	-23.65M	-21.9M	-22.21M	-24.77M	-33.02M	-48.82M	-38.24M
Pretax Margin %	-	-	-	-	-	-	-21.66%	-32.06%	-602.69%	-
Income Tax+	7.87K	5.01K	0	173.36K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-21.02M	-24.32M	-26.6M	-23.65M	-21.9M	-22.21M	-24.77M	-33.02M	-48.82M	-38.24M
Net Margin %	-	-	-	-	-	-	-21.66%	-32.06%	-602.69%	-
Net Income Growth %	0.15%	-0.16%	-0.09%	0.11%	0.07%	-0.01%	-0.12%	-0.33%	-0.48%	0.22%
Net Income (Continuing)	-21.02M	-24.32M	-26.6M	-23.65M	-21.9M	-22.21M	-24.77M	-33.02M	-48.82M	-38.24M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-16.53	-15.06	-11.96	-6.69	-4.37	-1.83	-1.20	-1.37	-1.83	-1.27
EPS Growth %	0.39%	0.09%	0.21%	0.44%	0.35%	0.58%	0.34%	-0.14%	-0.34%	0.31%
EPS (Basic)	-16.53	-15.06	-11.96	-6.69	-4.37	-1.83	-1.20	-1.37	-1.83	-1.27
Diluted Shares Outstanding	1.27M	1.61M	2.23M	3.54M	4.98M	12.13M	20.57M	24.14M	26.6M	30.07M
Basic Shares Outstanding	1.27M	1.61M	2.23M	3.54M	4.98M	12.13M	20.57M	24.14M	26.6M	30.07M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	26.48M	22.39M	17.84M	14.33M	10.09M	64.92M	79.75M	110.94M	78.26M	74.51M
Cash & Short-Term Investments	25.64M	20.52M	17.4M	13.67M	9.25M	63.61M	77.83M	108.91M	76.68M	72.9M
Cash Only	25.64M	20.52M	17.4M	13.67M	9.25M	63.61M	77.83M	108.91M	76.68M	72.9M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	34.73K	34.73K	0	40.08K	117.93K	68K	442K	396K	226K	357K
Total Non-Current Assets+	106.11K	138.41K	498.15K	559.79K	1.58M	1.47M	639K	3.25M	3.18M	2.39M
Property, Plant & Equipment	106.11K	88.55K	57.35K	118.8K	1.14M	1.03M	639K	2.95M	2.87M	2.07M
Fixed Asset Turnover	-	-	-	-	-	-	1.79x	0.35x	0.03x	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	49.86K	49.86K	49.86K	391.33K	391K	0	0	313K	324K
Other Non-Current Assets	0	0	390.94K	391.13K	49.86K	50K	0	302K	0	0
Total Assets+	26.59M	22.53M	18.34M	14.89M	11.67M	66.4M	80.39M	114.19M	81.44M	76.9M
Asset Turnover	-	-	-	-	-	-	0.01x	0.01x	0.00x	-
Asset Growth %	2.51%	-0.15%	-0.19%	-0.19%	-0.22%	4.69%	0.21%	0.42%	-0.29%	-0.06%
Total Current Liabilities+	4.61M	4.52M	4.67M	6.06M	5.34M	4.77M	6.84M	10.63M	8.49M	8.15M
Accounts Payable	1.47M	4.19M	4.65M	5.81M	4.6M	4.34M	5.54M	10.13M	7.95M	7.57M
Days Payables Outstanding	-	19.75K	30.34K	41.84K	4K	3.54K	3.86K	-	-	3.41K
Short-Term Debt	265.69K	0	0	249.24K	381K	427K	0	0	541K	0
Deferred Revenue (Current)	25K	0	0	-1000K	-1000K	0	0	0	0	0
Other Current Liabilities	2.87M	325.68K	15.92K	0	4.6M	0	998K	0	0	0
Current Ratio	5.74x	4.95x	3.82x	2.36x	1.89x	13.62x	11.66x	10.44x	9.21x	9.14x
Quick Ratio	5.74x	4.95x	3.82x	2.36x	1.89x	13.62x	11.66x	10.44x	9.21x	9.14x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	13.35K	682.31K	311K	3K	37.08M	36.57M	35.99M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	13.35K	682K	311K	3K	2.08M	1.57M	993K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	311	0	0	35M	0	0
Total Liabilities	4.61M	4.52M	4.67M	6.08M	6.03M	5.08M	6.84M	47.71M	45.07M	44.14M
Total Debt+	265.69K	0	0	262.59K	1.43M	738K	310K	2.58M	2.11M	1.57M
Net Debt	-25.38M	-20.52M	-17.4M	-13.41M	-7.83M	-62.87M	-77.52M	-106.33M	-74.56M	-71.33M
Debt / Equity	0.01x	-	-	0.03x	0.25x	0.01x	0.00x	0.04x	0.06x	0.05x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3155.82x	-5361.89x	-4955.99x	-137.44x	-	-	-	-	-	-
Total Equity+	21.97M	18.01M	13.67M	8.81M	5.64M	61.32M	73.55M	66.48M	36.38M	32.76M
Equity Growth %	12.43%	-0.18%	-0.24%	-0.36%	-0.36%	9.86%	0.2%	-0.1%	-0.45%	-0.1%
Book Value per Share	17.28	11.15	6.14	2.49	1.13	5.05	3.58	2.75	1.37	1.09
Total Shareholders' Equity	21.97M	18.01M	13.67M	8.81M	5.64M	61.32M	73.55M	66.48M	36.38M	32.76M
Common Stock	44.07K	55.8K	80.07K	115.7K	164.7K	18K	22K	26K	28K	31K
Retained Earnings	-112.23M	-136.55M	-163.15M	-186.86M	-208.76M	-230.97M	-255.75M	-288.76M	-337.58M	-375.83M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-92.93K	-170.45K	-215.66K	-266.38K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-18.54M	-20.79M	-21.55M	-20.57M	-21.46M	-21.62M	-20.87M	8.64M	-47.34M	-33.07M
Operating CF Margin %	-	-	-	-	-	-	-18.24%	8.39%	-584.38%	-
Operating CF Growth %	-0.29%	-0.12%	-0.04%	0.05%	-0.04%	-0.01%	0.03%	1.41%	-6.48%	0.3%
Net Income	-21.03M	-24.32M	-26.6M	-23.65M	-21.9M	-22.21M	-24.77M	-33.02M	-48.82M	-38.24M
Depreciation & Amortization	53.47K	77.52K	55.94K	50.72K	420.09K	447K	524K	699K	790K	811K
Stock-Based Compensation	7.06M	4.3M	3.49M	1.8M	1.29M	1.25M	1.69M	2.79M	0	5.29M
Deferred Taxes	-7.06M	-6.83M	0	0	-3.39M	-2.4M	-1.55M	402K	0	0
Other Non-Cash Items	-3.81M	-2.53M	-304.12K	766.6K	3.39M	2.4M	1.55M	-402K	3.84M	0
Working Capital Changes	-821.22K	1.69M	1.8M	1.23M	-1.28M	-1.1M	1.69M	38.17M	-3.15M	-932K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-793.95K	2.72M	405.21K	1.13M	-1.26M	-257K	1.2M	4.59M	-2.18M	-387K
Cash from Investing+	-47.79K	-109.82K	-380.95K	-96.09K	-63.89K	-253K	-133K	-366K	-153K	-11K
Capital Expenditures	-47.79K	-59.96K	-24.74K	-96.09K	-63.89K	-253K	-133K	-366K	-153K	-11K
CapEx % of Revenue	-	-	-	-	-	-	0.12%	0.36%	1.89%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-49.86K	-356.21K	0	0	0	0	0	0	0
Cash from Financing+	37.53M	15.78M	18.81M	16.98M	17.11M	76.18M	35.22M	23.11M	14.87M	29.32M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	-1.27K	-1K	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	173.62K	18.11K	0	4.85K	1.51M	48K	6K	0	0	75K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-18.59M	-20.85M	-21.58M	-20.67M	-21.53M	-21.87M	-21M	8.28M	-47.49M	-33.08M
FCF Margin %	-	-	-	-	-	-	-18.36%	8.04%	-586.27%	-
FCF Growth %	-0.28%	-0.12%	-0.03%	0.04%	-0.04%	-0.02%	0.04%	1.39%	-6.74%	0.3%
FCF per Share	-14.62	-12.91	-9.70	-5.85	-4.33	-1.80	-1.02	0.34	-1.78	-1.10
FCF Conversion (FCF/Net Income)	0.88x	0.85x	0.81x	0.87x	0.98x	0.97x	0.84x	-0.26x	0.97x	0.86x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-209.71%	-121.66%	-167.94%	-210.41%	-302.95%	-66.35%	-36.74%	-47.16%	-94.92%	-110.63%
Gross Margin	-	-	-	-	-	-	54.2%	100%	100%	-
Net Margin	-	-	-	-	-	-	-2165.56%	-3205.53%	-60269.14%	-
Debt / Equity	0.01x	-	-	0.03x	0.25x	0.01x	0.00x	0.04x	0.06x	0.05x
Interest Coverage	-3155.82x	-5361.89x	-4955.99x	-137.44x	-	-	-	-	-	-
FCF Conversion	0.88x	0.85x	0.81x	0.87x	0.98x	0.97x	0.84x	-0.26x	0.97x	0.86x
Revenue Growth	-	-	-	-	-	-	-	-9.96%	-92.14%	-100%

Revenue by Segment

	2023
Other Revenue Member	81K
Other Revenue Member Growth	-

Frequently Asked Questions

Growth & Financials

Actinium Pharmaceuticals, Inc. (ATNM) reported $0.1M in revenue for fiscal year 2024.

Actinium Pharmaceuticals, Inc. (ATNM) saw revenue decline by 100.0% over the past year.

Actinium Pharmaceuticals, Inc. (ATNM) reported a net loss of $34.6M for fiscal year 2024.

Dividend & Returns

Actinium Pharmaceuticals, Inc. (ATNM) has a return on equity (ROE) of -110.6%. Negative ROE indicates the company is unprofitable.

Actinium Pharmaceuticals, Inc. (ATNM) had negative free cash flow of $25.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Actinium Pharmaceuticals, Inc. (ATNM) 10-Year Financial Performance & Capital Metrics

ATNM • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

Revenue $0 -100.0%
EBITDA -$41M +19.2%
Net Income -$38M +21.7%
EPS (Diluted) -1.27 +30.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -110.63% -16.5%
ROIC -
Debt/Equity 0.05 -17.3%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 13.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM11.11%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM15.44%

EPS CAGR

10Y-

5Y-

3Y-

TTM21.43%

ROCE

10Y Avg-131.46%

5Y Avg-51.93%

3Y Avg-52.26%

Latest-59.45%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	1.14M	1.03M	81K	0
Revenue Growth %	-	-	-	-	-	-	-	-0.1%	-0.92%	-1%
Cost of Goods Sold+	0	77.52K	55.94K	50.72K	420.09K	447K	524K	0	0	811K
COGS % of Revenue	-	-	-	-	-	-	0.46%	-	-	-
Gross Profit+	-53.47K	-77.52K	-55.94K	-50.72K	-420.09K	-447K	620K	1.03M	81K	-811K
Gross Margin %	-	-	-	-	-	-	0.54%	1%	1%	-
Gross Profit Growth %	-	-0.45%	0.28%	0.09%	-7.28%	-0.06%	2.39%	0.66%	-0.92%	-11.01%
Operating Expenses+	24.83M	26.85M	26.91M	23.83M	21.65M	21.95M	25.58M	35.13M	52M	41.31M
OpEx % of Revenue	-	-	-	-	-	-	22.36%	34.11%	641.99%	-
Selling, General & Admin	11.46M	9.27M	9.15M	6.73M	5.1M	6.31M	8.08M	12M	13.33M	12.08M
SG&A % of Revenue	-	-	-	-	-	-	7.06%	11.65%	164.58%	-
Research & Development	13.31M	17.5M	17.7M	17.09M	16.55M	16.09M	17.51M	23.14M	38.67M	30.05M
R&D % of Revenue	-	-	-	-	-	-	15.3%	22.46%	477.41%	-
Other Operating Expenses	53.47K	77.52K	55.94K	0	0	-447K	0	0	0	-811K
Operating Income+	-24.83M	-26.85M	-26.91M	-23.83M	-22.07M	-22.39M	-24.96M	-34.1M	-51.92M	-42.12M
Operating Margin %	-	-	-	-	-	-	-21.82%	-33.11%	-640.99%	-
Operating Income Growth %	-0.1%	-0.08%	-0%	0.11%	0.07%	-0.01%	-0.11%	-0.37%	-0.52%	0.19%
EBITDA+	-24.78M	-26.77M	-26.86M	-23.78M	-21.65M	-21.95M	-24.44M	-33.41M	-51.13M	-41.31M
EBITDA Margin %	-	-	-	-	-	-	-21.36%	-32.43%	-631.23%	-
EBITDA Growth %	-0.1%	-0.08%	-0%	0.11%	0.09%	-0.01%	-0.11%	-0.37%	-0.53%	0.19%
D&A (Non-Cash Add-back)	53.47K	77.52K	55.94K	50.72K	420.09K	447K	524K	699K	790K	811K
EBIT	-24.83M	-26.85M	-26.91M	-23.83M	-21.9M	-22.21M	-24.77M	-34.1M	-51.92M	-38.24M
Net Interest Income+	0	0	0	0	0	178K	190K	1.09M	3.1M	3.88M
Interest Income	0	0	5.43K	173.36K	172.39K	178K	190K	1.09M	3.1M	3.88M
Interest Expense	7.87K	5.01K	5.43K	173.36K	0	0	0	0	0	0
Other Income/Expense	3.8M	2.53M	309.55K	173.36K	172.39K	178K	190K	1.09M	3.1M	3.88M
Pretax Income+	-21.02M	-24.32M	-26.6M	-23.65M	-21.9M	-22.21M	-24.77M	-33.02M	-48.82M	-38.24M
Pretax Margin %	-	-	-	-	-	-	-21.66%	-32.06%	-602.69%	-
Income Tax+	7.87K	5.01K	0	173.36K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-21.02M	-24.32M	-26.6M	-23.65M	-21.9M	-22.21M	-24.77M	-33.02M	-48.82M	-38.24M
Net Margin %	-	-	-	-	-	-	-21.66%	-32.06%	-602.69%	-
Net Income Growth %	0.15%	-0.16%	-0.09%	0.11%	0.07%	-0.01%	-0.12%	-0.33%	-0.48%	0.22%
Net Income (Continuing)	-21.02M	-24.32M	-26.6M	-23.65M	-21.9M	-22.21M	-24.77M	-33.02M	-48.82M	-38.24M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-16.53	-15.06	-11.96	-6.69	-4.37	-1.83	-1.20	-1.37	-1.83	-1.27
EPS Growth %	0.39%	0.09%	0.21%	0.44%	0.35%	0.58%	0.34%	-0.14%	-0.34%	0.31%
EPS (Basic)	-16.53	-15.06	-11.96	-6.69	-4.37	-1.83	-1.20	-1.37	-1.83	-1.27
Diluted Shares Outstanding	1.27M	1.61M	2.23M	3.54M	4.98M	12.13M	20.57M	24.14M	26.6M	30.07M
Basic Shares Outstanding	1.27M	1.61M	2.23M	3.54M	4.98M	12.13M	20.57M	24.14M	26.6M	30.07M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	26.48M	22.39M	17.84M	14.33M	10.09M	64.92M	79.75M	110.94M	78.26M	74.51M
Cash & Short-Term Investments	25.64M	20.52M	17.4M	13.67M	9.25M	63.61M	77.83M	108.91M	76.68M	72.9M
Cash Only	25.64M	20.52M	17.4M	13.67M	9.25M	63.61M	77.83M	108.91M	76.68M	72.9M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	34.73K	34.73K	0	40.08K	117.93K	68K	442K	396K	226K	357K
Total Non-Current Assets+	106.11K	138.41K	498.15K	559.79K	1.58M	1.47M	639K	3.25M	3.18M	2.39M
Property, Plant & Equipment	106.11K	88.55K	57.35K	118.8K	1.14M	1.03M	639K	2.95M	2.87M	2.07M
Fixed Asset Turnover	-	-	-	-	-	-	1.79x	0.35x	0.03x	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	49.86K	49.86K	49.86K	391.33K	391K	0	0	313K	324K
Other Non-Current Assets	0	0	390.94K	391.13K	49.86K	50K	0	302K	0	0
Total Assets+	26.59M	22.53M	18.34M	14.89M	11.67M	66.4M	80.39M	114.19M	81.44M	76.9M
Asset Turnover	-	-	-	-	-	-	0.01x	0.01x	0.00x	-
Asset Growth %	2.51%	-0.15%	-0.19%	-0.19%	-0.22%	4.69%	0.21%	0.42%	-0.29%	-0.06%
Total Current Liabilities+	4.61M	4.52M	4.67M	6.06M	5.34M	4.77M	6.84M	10.63M	8.49M	8.15M
Accounts Payable	1.47M	4.19M	4.65M	5.81M	4.6M	4.34M	5.54M	10.13M	7.95M	7.57M
Days Payables Outstanding	-	19.75K	30.34K	41.84K	4K	3.54K	3.86K	-	-	3.41K
Short-Term Debt	265.69K	0	0	249.24K	381K	427K	0	0	541K	0
Deferred Revenue (Current)	25K	0	0	-1000K	-1000K	0	0	0	0	0
Other Current Liabilities	2.87M	325.68K	15.92K	0	4.6M	0	998K	0	0	0
Current Ratio	5.74x	4.95x	3.82x	2.36x	1.89x	13.62x	11.66x	10.44x	9.21x	9.14x
Quick Ratio	5.74x	4.95x	3.82x	2.36x	1.89x	13.62x	11.66x	10.44x	9.21x	9.14x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	13.35K	682.31K	311K	3K	37.08M	36.57M	35.99M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	13.35K	682K	311K	3K	2.08M	1.57M	993K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	311	0	0	35M	0	0
Total Liabilities	4.61M	4.52M	4.67M	6.08M	6.03M	5.08M	6.84M	47.71M	45.07M	44.14M
Total Debt+	265.69K	0	0	262.59K	1.43M	738K	310K	2.58M	2.11M	1.57M
Net Debt	-25.38M	-20.52M	-17.4M	-13.41M	-7.83M	-62.87M	-77.52M	-106.33M	-74.56M	-71.33M
Debt / Equity	0.01x	-	-	0.03x	0.25x	0.01x	0.00x	0.04x	0.06x	0.05x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3155.82x	-5361.89x	-4955.99x	-137.44x	-	-	-	-	-	-
Total Equity+	21.97M	18.01M	13.67M	8.81M	5.64M	61.32M	73.55M	66.48M	36.38M	32.76M
Equity Growth %	12.43%	-0.18%	-0.24%	-0.36%	-0.36%	9.86%	0.2%	-0.1%	-0.45%	-0.1%
Book Value per Share	17.28	11.15	6.14	2.49	1.13	5.05	3.58	2.75	1.37	1.09
Total Shareholders' Equity	21.97M	18.01M	13.67M	8.81M	5.64M	61.32M	73.55M	66.48M	36.38M	32.76M
Common Stock	44.07K	55.8K	80.07K	115.7K	164.7K	18K	22K	26K	28K	31K
Retained Earnings	-112.23M	-136.55M	-163.15M	-186.86M	-208.76M	-230.97M	-255.75M	-288.76M	-337.58M	-375.83M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-92.93K	-170.45K	-215.66K	-266.38K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-18.54M	-20.79M	-21.55M	-20.57M	-21.46M	-21.62M	-20.87M	8.64M	-47.34M	-33.07M
Operating CF Margin %	-	-	-	-	-	-	-18.24%	8.39%	-584.38%	-
Operating CF Growth %	-0.29%	-0.12%	-0.04%	0.05%	-0.04%	-0.01%	0.03%	1.41%	-6.48%	0.3%
Net Income	-21.03M	-24.32M	-26.6M	-23.65M	-21.9M	-22.21M	-24.77M	-33.02M	-48.82M	-38.24M
Depreciation & Amortization	53.47K	77.52K	55.94K	50.72K	420.09K	447K	524K	699K	790K	811K
Stock-Based Compensation	7.06M	4.3M	3.49M	1.8M	1.29M	1.25M	1.69M	2.79M	0	5.29M
Deferred Taxes	-7.06M	-6.83M	0	0	-3.39M	-2.4M	-1.55M	402K	0	0
Other Non-Cash Items	-3.81M	-2.53M	-304.12K	766.6K	3.39M	2.4M	1.55M	-402K	3.84M	0
Working Capital Changes	-821.22K	1.69M	1.8M	1.23M	-1.28M	-1.1M	1.69M	38.17M	-3.15M	-932K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-793.95K	2.72M	405.21K	1.13M	-1.26M	-257K	1.2M	4.59M	-2.18M	-387K
Cash from Investing+	-47.79K	-109.82K	-380.95K	-96.09K	-63.89K	-253K	-133K	-366K	-153K	-11K
Capital Expenditures	-47.79K	-59.96K	-24.74K	-96.09K	-63.89K	-253K	-133K	-366K	-153K	-11K
CapEx % of Revenue	-	-	-	-	-	-	0.12%	0.36%	1.89%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-49.86K	-356.21K	0	0	0	0	0	0	0
Cash from Financing+	37.53M	15.78M	18.81M	16.98M	17.11M	76.18M	35.22M	23.11M	14.87M	29.32M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	-1.27K	-1K	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	173.62K	18.11K	0	4.85K	1.51M	48K	6K	0	0	75K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-18.59M	-20.85M	-21.58M	-20.67M	-21.53M	-21.87M	-21M	8.28M	-47.49M	-33.08M
FCF Margin %	-	-	-	-	-	-	-18.36%	8.04%	-586.27%	-
FCF Growth %	-0.28%	-0.12%	-0.03%	0.04%	-0.04%	-0.02%	0.04%	1.39%	-6.74%	0.3%
FCF per Share	-14.62	-12.91	-9.70	-5.85	-4.33	-1.80	-1.02	0.34	-1.78	-1.10
FCF Conversion (FCF/Net Income)	0.88x	0.85x	0.81x	0.87x	0.98x	0.97x	0.84x	-0.26x	0.97x	0.86x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-209.71%	-121.66%	-167.94%	-210.41%	-302.95%	-66.35%	-36.74%	-47.16%	-94.92%	-110.63%
Gross Margin	-	-	-	-	-	-	54.2%	100%	100%	-
Net Margin	-	-	-	-	-	-	-2165.56%	-3205.53%	-60269.14%	-
Debt / Equity	0.01x	-	-	0.03x	0.25x	0.01x	0.00x	0.04x	0.06x	0.05x
Interest Coverage	-3155.82x	-5361.89x	-4955.99x	-137.44x	-	-	-	-	-	-
FCF Conversion	0.88x	0.85x	0.81x	0.87x	0.98x	0.97x	0.84x	-0.26x	0.97x	0.86x
Revenue Growth	-	-	-	-	-	-	-	-9.96%	-92.14%	-100%

Revenue by Segment

	2023
Other Revenue Member	81K
Other Revenue Member Growth	-

Frequently Asked Questions

Growth & Financials

Actinium Pharmaceuticals, Inc. (ATNM) reported $0.1M in revenue for fiscal year 2024.

Actinium Pharmaceuticals, Inc. (ATNM) saw revenue decline by 100.0% over the past year.

Actinium Pharmaceuticals, Inc. (ATNM) reported a net loss of $34.6M for fiscal year 2024.

Dividend & Returns

Actinium Pharmaceuticals, Inc. (ATNM) has a return on equity (ROE) of -110.6%. Negative ROE indicates the company is unprofitable.

Actinium Pharmaceuticals, Inc. (ATNM) had negative free cash flow of $25.0M in fiscal year 2024, likely due to heavy capital investments.